FY2017 EPS Estimates for OraSure Technologies, Inc. Lowered by Jefferies Group (OSUR)
OraSure Technologies, Inc. (NASDAQ:OSUR) – Equities researchers at Jefferies Group dropped their FY2017 earnings per share estimates for OraSure Technologies in a research note issued on Thursday. Jefferies Group analyst B. Couillard now forecasts that the medical instruments supplier will post earnings per share of $0.47 for the year, down from their previous estimate of $0.49. Jefferies Group currently has a “Hold” rating on the stock. Jefferies Group also issued estimates for OraSure Technologies’ Q1 2018 earnings at $0.07 EPS, Q2 2018 earnings at $0.09 EPS, Q3 2018 earnings at $0.09 EPS, Q4 2018 earnings at $0.11 EPS, FY2018 earnings at $0.35 EPS and FY2019 earnings at $0.40 EPS.
OSUR has been the topic of a number of other reports. ValuEngine downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Thursday. Canaccord Genuity raised their price target on shares of OraSure Technologies from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, August 3rd. Zacks Investment Research upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research note on Wednesday, September 20th. Finally, BidaskClub downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. OraSure Technologies has a consensus rating of “Buy” and a consensus price target of $18.21.
Shares of OraSure Technologies (NASDAQ:OSUR) opened at $14.82 on Monday. OraSure Technologies has a one year low of $7.09 and a one year high of $23.01. The firm has a market cap of $881.18, a P/E ratio of 28.50, a PEG ratio of 2.22 and a beta of 1.39.
OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 EPS for the quarter, meeting the consensus estimate of $0.09. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. The firm had revenue of $42.30 million for the quarter, compared to analyst estimates of $40.87 million. During the same period last year, the firm earned $0.11 EPS. The business’s quarterly revenue was up 31.0% compared to the same quarter last year.
Large investors have recently bought and sold shares of the stock. Victory Capital Management Inc. acquired a new stake in OraSure Technologies during the 1st quarter worth approximately $100,000. First Mercantile Trust Co. acquired a new stake in OraSure Technologies during the 2nd quarter worth approximately $104,000. Pinebridge Investments L.P. acquired a new stake in OraSure Technologies during the 2nd quarter worth approximately $131,000. Profund Advisors LLC boosted its position in OraSure Technologies by 2.8% during the 2nd quarter. Profund Advisors LLC now owns 10,903 shares of the medical instruments supplier’s stock worth $188,000 after buying an additional 293 shares during the period. Finally, ETRADE Capital Management LLC acquired a new stake in OraSure Technologies during the 2nd quarter worth approximately $193,000. Institutional investors and hedge funds own 92.88% of the company’s stock.
In related news, CEO Douglas A. Michels sold 25,000 shares of OraSure Technologies stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $22.55, for a total transaction of $563,750.00. Following the sale, the chief executive officer now directly owns 743,058 shares in the company, valued at approximately $16,755,957.90. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Douglas A. Michels sold 22,923 shares of OraSure Technologies stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $23.00, for a total transaction of $527,229.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 61,110 shares of company stock worth $1,362,463. 6.40% of the stock is currently owned by corporate insiders.
About OraSure Technologies
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.